120 related articles for article (PubMed ID: 16870107)
1. Juvenile psoriatic arthritis and acquired sensorineural hearing loss in a teenager: is there an association?
Giani T; Simonini G; Lunardi C; Puccetti A; De Martino M; Falcini F
Clin Exp Rheumatol; 2006; 24(3):344-6. PubMed ID: 16870107
[TBL] [Abstract][Full Text] [Related]
2. Sensorineural hearing loss associated with psoriatic arthritis.
Srikumar S; Deepak MK; Basu S; Kumar BN
J Laryngol Otol; 2004 Nov; 118(11):909-11. PubMed ID: 15638985
[TBL] [Abstract][Full Text] [Related]
3. Etanercept therapy for immune-mediated cochleovestibular disorders: a multi-center, open-label, pilot study.
Matteson EL; Choi HK; Poe DS; Wise C; Lowe VJ; McDonald TJ; Rahman MU
Arthritis Rheum; 2005 Jun; 53(3):337-42. PubMed ID: 15934127
[TBL] [Abstract][Full Text] [Related]
4. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
Lobo D; Trinidad A; García-Berrocal JR; Verdaguer JM; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Jul; 263(7):622-6. PubMed ID: 16547758
[TBL] [Abstract][Full Text] [Related]
5. Successful use of etanercept in acquired angioedema in a patient with psoriatic arthritis.
Rottem M; Mader R
J Rheumatol; 2010 Jan; 37(1):209. PubMed ID: 20040647
[No Abstract] [Full Text] [Related]
6. Efficacy of etanercept in lymphedema associated with psoriatic arthritis.
Lekpa FK; Economu-Dubosc A; Fevre C; Claudepierre P; Chevalier X
J Rheumatol; 2009 Jan; 36(1):207-8. PubMed ID: 19208540
[No Abstract] [Full Text] [Related]
7. Etanercept is safely used for treating psoriatic arthritis in a patient complicated with type 1 hereditary angioedema.
Umegaki N; Kira M; Horiuchi T; Itoi S; Tani M; Yokomi A; Tanemura A; Miyahara H; Hatanaka M; Kitamura H; Kitano E; Katayama I
Mod Rheumatol; 2012 Nov; 22(6):928-30. PubMed ID: 22310967
[TBL] [Abstract][Full Text] [Related]
8. Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
Kowalzick L; Bertolini J; Baumann C; Walther B; Truhm B; Eickenscheidt L
J Dtsch Dermatol Ges; 2013 May; 11(5):447-9. PubMed ID: 23343137
[No Abstract] [Full Text] [Related]
9. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years.
Yazici Y; Erkan D; Lockshin MD
Clin Exp Rheumatol; 2002; 20(1):115. PubMed ID: 11892697
[No Abstract] [Full Text] [Related]
10. Etanercept, a tumour necrosis factor alpha receptor antagonist, and methotrexate in acute sensorineural hearing loss.
Street I; Jobanputra P; Proops DW
J Laryngol Otol; 2006 Dec; 120(12):1064-6. PubMed ID: 17040588
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
12. Etanercept (Enbrel) -- an update.
Goffe B
Skin Therapy Lett; 2004 Dec-2005 Jan; 9(10):1-4, 9. PubMed ID: 15657632
[TBL] [Abstract][Full Text] [Related]
13. No evidence-based practice by biased information from systematic reviews: the case of etanercept and infliximab for the treatment of psoriatic arthritis.
Corrao S; Puleo A; Pistone G; Calvo L; Scaglione R; Licata G
Clin Exp Rheumatol; 2008; 26(1):164; author reply 165. PubMed ID: 18328174
[No Abstract] [Full Text] [Related]
14. [Therapy of psoriasis vulgaris and psoriatic arthritis with etanercept].
Mrowietz U; Barth J; Boehncke WH; Rosenbach T; Wozel G
J Dtsch Dermatol Ges; 2005 Jun; 3(6):470-2. PubMed ID: 15892851
[No Abstract] [Full Text] [Related]
15. Etanercept: an evolving role in psoriasis and psoriatic arthritis.
Prodanovich S; Ricotti C; Glick BP; Inverardi L; Leonardi CL; Kerdel F
Am J Clin Dermatol; 2010; 11 Suppl 1():3-9. PubMed ID: 20586498
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
17. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis.
Yazici Y; Erkan D; Lockshin MD
Clin Exp Rheumatol; 2000; 18(6):732-4. PubMed ID: 11138337
[TBL] [Abstract][Full Text] [Related]
18. One million U.S. adults may suffer from psoriatic arthritis.
Dermatol Nurs; 2002 Jun; 14(3):207-8. PubMed ID: 12099074
[No Abstract] [Full Text] [Related]
19. Extracapillary glomerulonephritis during etanercept treatment for juvenile psoriatic arthritis.
Menè P; Franeta AJ; Conti G; Stoppacciaro A; Chimenz R; Fede A; Gallizzi R; Fede C
Clin Exp Rheumatol; 2010; 28(1):91-3. PubMed ID: 20346246
[TBL] [Abstract][Full Text] [Related]
20. Psoriatic arthritis patients doing better on infliximab than etanercept.
Smith N; Gadsby K; Deighton C
Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
[No Abstract] [Full Text] [Related]
[Next] [New Search]
